Abstract:Background and objective: Overexpression of ATP-binding cassette (ABC) transporters, which play a key role in the development of multidrug resistance (MDR), is a significant impediment to successful cancer treatment. Sunitinib is an ATP-competitive multi-targeted tyrosine kinase inhibitor. In this study, we investigated in vitro the possible interaction of sunitinib with the major members of the ABC transporters: P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP). Methods: Cytotoxicity tests were performed using the MTT assay; The intracellular accumulation of doxorubicin and rhodamine 123 (Rho123) was analysed by flow cytometry; Membrane vesicles were prepared by the nitrogen cavitation and transport assays were performed using the rapid filtration method to confirm the effect of sunitinib on the transporter activity of ABCG2; Western Blotting was used to determine the protein expression; and reverse transcription-PCR was used to assess the expression of ABCG2 at mRNA level. Results: The IC 50 concentration for parental cell line S1 to topotecan or doxorubicin were 0.135 ± 0.056 µM and 0.165 ± 0.009 µM, respectively; However, the concentration of topotecan or doxorubicin required to inhibit ABCG2- overexpressing cell line S1-M1-80 by 50% was about 5.132 ± 2.024 and 6.845 ± 1.035 µM; Coincubation with 2.5 sunitinib, the concentrations required to inhibit the growth of S1-M1-80 cells by 50% for topotecan was 0.091 ± 0.012 µM, and for doxorubicin was 0.181 ± 0.037 µM, respectively. Sunitinib potently reverses ABCG2-mediated resistance to topotecan and doxorubicin in vitro and has no significant reversal effect on ABCB1-, ABCC1- and LRP-mediated drug resistance, although a small synergetic effect was observed in combining sunitinib and conventional chemotherapeutic agents in ABCB1-overexpressing MCF-7/adr and parental sensitive MCF-7 cells, ABCC1-overexpressing C-A120 and parental sensitive KB-3-1 cells. Sunitinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and remarkably inhibited the efflux of rhodamine-123 in ABCG2-overexpressing cells, and also profoundly inhibited the transport of [ 3 H]-methotrexate by ABCG2. However, sunitinib did not affect the expression of ABCG2 at mRNA or protein levels. In addition, sunitinib did not block the phosphorylation of Akt and Erk1/2 in ABCG2-overexpressing or parental sensitive cells. Conclusions: Sunitinib reverses ABCG2-mediated MDR through inhibiting the drug efflux function of ABCG2. These findings may be useful for cancer combinational therapy with sunitinib in the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1533.

Abstract 1531: BCR-Abl Tyrosine Kinase Inhibitor Nilotinib (tasigna®) Reverses ABCB1/Pgp- and ABCG2/BCRP-mediated Multidrug Resistance

Nilotinib (AMN107, Tasigna®) Reverses Multidrug Resistance by Inhibiting the Activity of the ABCB1/Pgp and ABCG2/BCRP/MXR Transporters

Nilotinib Potentiates Anticancer Drug Sensitivity in Murine ABCB1-, ABCG2-, and ABCC10-multidrug Resistance Xenograft Models.

Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10).

Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.

Nilotinib Enhances The Efficacy Of Conventional Chemotherapeutic Drugs In Cd34(+)Cd38(-) Stem Cells And Abc Transporter Overexpressing Leukemia Cells

Abstract 1519: Tyrosine kinase inhibitors are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance

Abstract 1533: Sunitinib reverses ABCG2/BCRP-mediated multidrug resistance by inhibiting its efflux activity

Cancer esearch apeutics , Targets , and Chemical Biology tinib ( YN 968 D 1 ) Reverses Multidrug Resistance by biting the Efflux Function of Multiple ATP-Binding R sette Transporters

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations

Tandutinib (mln518/ct53518) Targeted to Stem-Like Cells by Inhibiting the Function of Atp-Binding Cassette Subfamily G Member 2

[Inducing Apoptosis and Reversal Effect of Nilotinib in Combination with Tetrandrine on Multidrug Resistance of K562/A02 Cell Line].

Study on the Relevance of Inducing Apoptosis and Reversal Effect of Nilotinib in Combination with Tet on Multidrug Reststahoe of K562/A02 Cell Line

Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance in Vitro, in Vivo, and Ex Vivo

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Abstract 773: Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

Study on Reversal Effect of Nilotinib in Combination with 5-Brtet on Multidrug Resistance of K562/A02 Cell Line

Tandutinib (MLN518) Reverses Multidrug Resistance by Inhibiting the Efflux Activity of the Multidrug Resistance Protein 7 (ABCC10).

Reversal of Multidrug-Resistance in Human Leukemia Cell Line K562/A02 by Tyrosine Kinase Inhibitors.

Reversal of ABCB1- and ABCG2-mediated MDR byerlotinib (tarceva, OSI-774)